MIAMI--(BUSINESS WIRE)--Brickell Biotech, Inc. (“Brickell“), a clinical-stage pharmaceutical company focused on the development of differentiated, innovative therapeutics to satisfy current unmet human needs in the global dermatology markets, today announced that it has entered into a license agreement with Merz North America, Inc. (“Merz”). The agreement grants Merz an exclusive North American license, with certain additional international rights, to develop and commercialize a completely novel retinoid compound, BBI-3000, for the treatment of skin conditions known to be responsive to retinoid agents, such as acne and psoriasis.
Help employers find you! Check out all the jobs and post your resume.
